Synapse loss is associated with some of the most devastating and debilitating central nervous system (CNS) conditions, including Alzheimer’s, ALS and schizophrenia. Much of CNS drug development has focused on mitigating the accumulation of damaging proteins, including mutant SOD1 in ALS, amyloid beta in Alzheimer’s, or fine-tuning receptor signaling, such as dopaminergic pathways in schizophrenia.…
Eighteen months. That is how long someone with Alzheimer’s may wait to find out whether a treatment made any difference at all. A recent Cochrane review sparked a lively discussion across the neurology community regarding anti-amyloid therapies for Alzheimer’s disease. The review highlighted a challenging reality: while these monoclonal antibodies are successfully removing amyloid plaques…
By Dr. Peter Vanderklish Many neurological disorders appear very different clinically, yet an important biological theme is emerging across them: early loss of synaptic connectivity. In a recent article published in The Scientist, Dr. Vanderklish, Chief Science Officer at Spinogenix, examines synapse loss as a point of convergence across conditions including Alzheimer’s disease, amyotrophic lateral…
Authored by Stella Sarraf, PhD CEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our time. However, the battle against Alzheimer’s is not confined to just one month. More than 55 million people worldwide are living with Alzheimer’s and related…
When Stead Impact Ventures Board Chair Jerre Stead sat down with Dr. Stella Sarraf, founder and CEO of Spinogenix, their discussion centered on one shared belief: patients deserve more than incremental progress. They deserve treatments that can truly change their lives. For Stella, that mission is deeply personal. As a daughter and caregiver, she’s seen…
Thank you to NeurologyLive for featuring, Dr. Sharron Gargosky, PhD, Chief Development Officer at Spinogenix, at the AAIC2025 in Toronto Sharron highlights key findings from our Phase 2a study on SPG302, a first-in-class synaptic regenerative therapy in Alzheimer’s disease participants in Australia. The study enrolled all Alzheimer patients with mild to moderate disease who were…
Posted in Life Science Podcast By: Ayesha Rashid, PhD In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Stella Sarraf, PhD, CEO and Founder of Spinogenix, a company pioneering novel neurodegenerative therapeutics designed to restore synapses with the potential to reverse cognitive and motor decline in conditions such as ALS, Alzheimer’s disease,…
We’re thrilled to share that our CEO and Founder, Stella Sarraf, PhD, has been named to Forbes 2025 Class of 50 Over 50: Innovation list. This recognition celebrates trailblazers who are redefining what’s possible in science, technology, and business—and we couldn’t be prouder to see Stella honored for her bold vision and unwavering commitment to…
By: Maggie McGrath, Forbes Staff andForbesWomen Team, Forbes Staff. Stella Sarraf founded drug discovery company Spinogenix in 2016 with a goal of finding a better way to treat neurodegenerative disorders—particularly Alzheimer’s Disease. Her approach looks at the brain’s synapses, which are the structures that allow our neurons to, effectively, talk to each other. “We have a…
June is Alzheimer’s and Brain Awareness Month. We take this timely opportunity to hear our Chief Science Officer, Dr. Peter Vanderklish, describe how SPG302 – our novel, regenerative medicine approach to neurodegenerative diseases – can be of benefit in Alzheimer’s disease. The burden of Alzheimer’s disease Over 44 million people worldwide suffer from Alzheimer’s disease,…